The Zepbound tracker for women on the dual-agonist path.
Tirzepatide for weight, the highest average weight loss in the class, and a tracker that takes the rest of your body seriously.
Zepbound is the weight-management version of tirzepatide. Same molecule as Mounjaro, indicated for weight rather than diabetes. The SURMOUNT trial program established the magnitude, average weight loss of around 20 percent at the highest dose over 72 weeks, the strongest number in the class so far.
Steady's Zepbound integration mirrors the medication's structure: the six-dose ladder built in, pause-the-titration support at any step, weekly injection logging with six-site rotation, and the same contraception warning the Eli Lilly label requires, four weeks of barrier protection after starting and after every dose increase, because tirzepatide can reduce oral contraceptive absorption.
The rate of weight loss on Zepbound at the highest dose can outrun the body's other systems if you let it. Steady's progress view shows the four-week moving average, not the morning weight, and surfaces the conversation worth having with your prescriber when the pace exceeds 1 percent per week sustained. Faster is not always better. Steadier almost always is.
Built around how this medication actually works.
The Zepbound dose ladder
2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg, with pause-at-any-step support.
Rate-aware progress
Four-week moving average, not morning weight. Pace warnings when you're losing faster than 1% per week.
Contraception window
Surfaces the four-week barrier-method advisory after every dose change, per the Lilly label.
Muscle preservation
120-gram protein target by default, plus a strength-training programme that fits a tired body.
What the studies actually say.
Evidence-based summaries of the papers that informed every part of this page. Each article cites its sources.
Mounjaro vs Wegovy: how to think about the choice
Tirzepatide loses more weight on average. Semaglutide has more years of safety data. The right answer is rarely about averages, here's the framework your prescriber is probably…
The month-four plateau on a GLP-1: why it happens, and what to do about it
The first eight weeks fly. Then the scale stops. This is not the drug failing, it is your body doing what bodies do. Here's the maths, and the three levers that move it again.
GLP-1s and the pill: a warning women on Mounjaro and Zepbound need to read
Tirzepatide can reduce the effectiveness of oral contraceptives. The label is clear about it; the conversation often isn't. Here is what to know, what to switch to, and for how…
Pausing your titration: the dose-hold most prescribers don't mention
Standard GLP-1 protocols climb the dose every four weeks. Nothing in the label requires that. The pause that protects skin, muscle, and mood is one of the most useful, and least…
Strength training on a GLP-1: a programme that fits a tired, hungry body
You don't need a gym membership. You need two sessions a week, each twenty to thirty minutes, that hit the muscles your body would otherwise quietly let go of. Here is the…
How to rotate your GLP-1 injection sites, and why it matters more than you think
Always the same spot. Always the same time. Always the same low-grade lump under the skin. Here is the rotation pattern that prevents lipohypertrophy, and the technique notes most…